Integra Lifesciences Holdings (IART) Total Current Liabilities (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Total Current Liabilities data on file, last reported at $346.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 62.24% year-over-year to $346.8 million; the trailing twelve-month figure through Mar 2026 stood at $346.8 million (down 62.24% YoY), and the FY2025 full-year result was $456.0 million, down 50.55% from the prior year.
• Total Current Liabilities eased to $346.8 million in Q1 2026, from $456.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $929.8 million in Q2 2025 to a low of $282.3 million in Q1 2023.
• A 5-year average of $472.9 million and a median of $346.8 million in 2026 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 203.73% in 2025 and plunged 62.24% in 2026, its largest moves.
• Tracing IART's Total Current Liabilities over 5 years: stood at $320.9 million in 2022, then decreased by 4.34% to $307.0 million in 2023, then surged by 200.39% to $922.1 million in 2024, then slumped by 50.55% to $456.0 million in 2025, then fell by 23.93% to $346.8 million in 2026.
• Business Quant data shows IART's Total Current Liabilities at $346.8 million in Q1 2026, $456.0 million in Q4 2025, and $364.1 million in Q3 2025.